mucinex

Collins Stewart has published a research report on Perrigo (NASDAQ: PRGO) after the company announced that it has received FDA approval on a store-brand for Mucinex. In the report, Collins Stewart writes, "We are reiterating our Buy rating and $117 price target for PRGO shares post the company's...